These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1643820)

  • 41. Low-dosage cefepime as treatment for serious bacterial infections.
    Giamarellou H
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():123-32. PubMed ID: 8150755
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparative study of ofloxacin and amoxycillin/clavulanate in hospitalized patients with lower respiratory tract infections.
    Khajotia R; Drlicek M; Vetter N
    J Antimicrob Chemother; 1990 Nov; 26 Suppl D():83-91. PubMed ID: 2286596
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral ciprofloxacin versus intravenous therapy with other non-quinolone agents: a study of 291 infections.
    Lorian V; Pavletich K
    Drugs Exp Clin Res; 1994; 20(5):209-14. PubMed ID: 7875058
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ofloxacin in the treatment of genito-urinary tract infections.
    Marone P; Concia E; Quarta V; Minoli L; Carnevale G
    J Chemother; 1989 Jul; 1(4 Suppl):854-5. PubMed ID: 16312670
    [No Abstract]   [Full Text] [Related]  

  • 45. Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization.
    Gentry LO; Rodriguez-Gomez G; Kohler RB; Khan FA; Rytel MW
    Am Rev Respir Dis; 1992 Jan; 145(1):31-5. PubMed ID: 1731595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial.
    Sanders WE; Morris JF; Alessi P; Makris AT; McCloskey RV; Trenholme GM; Iannini P; Bittner MJ
    Am J Med; 1991 Sep; 91(3):261-6. PubMed ID: 1892146
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A clinical experience of ofloxacin in patients with respiratory infection].
    Tanaka K; Suzuki H; Shimizu S; Otsuka H; Takagi H; Akisawa T; Narushima M; Tonotsuka H; Kaneshige H; Nakagami K
    Jpn J Antibiot; 1989 Aug; 42(8):1705-12. PubMed ID: 2810733
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Daily single-dose regimen and alternate-two-week triple-dose/day regimen of oral ofloxacin for the prophylaxis and control of exacerbations of chronic respiratory tract infections.
    Watanabe A; Oizumi K; Motomiya M; Nukiwa T
    Tohoku J Exp Med; 1995 May; 176(1):25-33. PubMed ID: 7482516
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ceftazidime in patients with Pseudomonas infections.
    Eron LJ; Park CH; Hixon DL; Goldenberg RI; Poretz DM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():161-9. PubMed ID: 6225762
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ofloxacin versus cephalexin for treating skin and soft tissue infections.
    Lipsky BA; Yarbrough DR; Walker FB; Powers RD; Morman MR
    Int J Dermatol; 1992 Jun; 31(6):443-5. PubMed ID: 1512105
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Evaluation of the effectiveness of ofloxacin in the treatment of respiratory tract].
    Chyrek-Borowska S; Siergiejko Z; Jakubicz P
    Pneumonol Alergol Pol; 1991; 59(1-2):22-7. PubMed ID: 1843882
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The use of ofloxacin in cystic fibrosis patients].
    Romano L; Girosi D; Spallone E; Parisi F; Minicucci L; Romano C
    Minerva Pediatr; 1992 Mar; 44(3):79-86. PubMed ID: 1518497
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oral ciprofloxacin therapy of infection caused by multiply resistant bacteria other than Pseudomonas aeruginosa.
    Scully BE; Neu HC
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():179-85. PubMed ID: 3804906
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
    Scully BE; Neu HC
    Am J Med; 1985 Feb; 78(2):251-61. PubMed ID: 4038574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Severe infections treated with intravenous ofloxacin: a prospective clinical multicentre Swiss study.
    Regamey C; Steinbach-Lebbin C
    J Antimicrob Chemother; 1990 Nov; 26 Suppl D():107-14. PubMed ID: 2286585
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group.
    Jones RN; Reller LB; Rosati LA; Erwin ME; Sanchez ML
    Diagn Microbiol Infect Dis; 1992 Jul; 15(5):425-34. PubMed ID: 1643819
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.
    Todd PA; Faulds D
    Drugs; 1991 Nov; 42(5):825-76. PubMed ID: 1723377
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical experience with amoxicillin in the treatment of skin infections.
    Pankey GA
    J Infect Dis; 1974 Jun; 129(0):suppl:S202-6. PubMed ID: 4276176
    [No Abstract]   [Full Text] [Related]  

  • 59. Gentamicin in the treatment of staphylococcal infections.
    Chambers WB; Pallagrosi AU
    J Int Med Res; 1977; 5(6):442-9. PubMed ID: 338394
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections.
    Bayer AS
    Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1102-10. PubMed ID: 2695331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.